文献速递血管炎

单克隆抗体与抗细胞因子生物制剂治疗川崎病:系统评价与Meta分析

Monoclonal antibody and anti-cytokine biologics for Kawasaki disease: A systematic review and meta-analysis.
PubMed 文献 · Semin Arthritis Rheum · 2021-08-02

该系统评价与Meta分析评估单克隆抗体及抗细胞因子生物制剂对川崎病患者的疗效,定性分析183项研究,定量合成4项RCT共456例患者。结果显示此类药物未降低冠状动脉异常(CAA)频率(RR 0.93,95%CI 0.65-1.32),但治疗抵抗频率降低(RR 0.60,95%CI 0.38-0.95),不良事件无显著差异。

要点

  • 单克隆抗体及抗细胞因子生物制剂未显著降低川崎病患儿冠状动脉异常频率。
  • 此类药物可降低治疗抵抗频率,RR为0.60(95%CI 0.38-0.95)。
  • 任何不良事件及药物相关不良事件在两组间均无统计学差异。

核心结论

  • 单克隆抗体和抗细胞因子生物制剂未能减少川崎病患者冠状动脉异常的发生频率。
  • 与常规IVIG治疗相比,此类药物可能降低治疗抵抗的频率。

研究设计与样本

  • 系统评价与Meta分析,纳入RCT及观察性研究,检索Cochrane Central、MEDLINE、EMBASE和ICUSHI数据库,方案注册于PROSPERO(CRD42016033079)。
  • 定性分析183项研究,定量合成纳入4项RCT共456例患者。

主要发现

  • 与常规IVIG治疗相比,单克隆抗体和抗细胞因子生物制剂未降低CAA频率(RR 0.93;95%CI 0.65-1.32;低确定性证据)。
  • 抗体类药物降低了治疗抵抗频率(RR 0.60;95%CI 0.38-0.95;中等确定性证据)。
  • 任何不良事件(RR 0.92;95%CI 0.80-1.06;低确定性证据)和药物相关不良事件(RR 1.10;95%CI 0.72-1.69;低确定性证据)组间无统计学差异。

关键数值与推荐

  • CAA频率:RR 0.93(95%CI 0.65-1.32),低确定性证据。
  • 治疗抵抗频率:RR 0.60(95%CI 0.38-0.95),中等确定性证据。
  • 任何不良事件:RR 0.92(95%CI 0.80-1.06),低确定性证据。
  • 药物相关不良事件:RR 1.10(95%CI 0.72-1.69),低确定性证据。

临床怎么用

  • 对于川崎病患者,单克隆抗体及抗细胞因子生物制剂不应以降低冠状动脉异常为主要目标使用。
  • 在常规IVIG治疗基础上,可考虑此类药物以降低治疗抵抗风险,但需结合中等确定性证据权衡。

局限性

  • 定量合成仅纳入4项RCT共456例患者,样本量有限。
  • CAA和不良事件结局的证据确定性为低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Kawasaki disease (KD) is a form of self-limiting vasculitis that causes coronary artery abnormalities in children. Although clinical trials of monoclonal antibodies and anti-cytokine biologics that block cytokine cascades have been conducted, the studies have revealed contradictory results. To examine the effectiveness of treatment with monoclonal antibodies and anti-cytokine biologics for KD patients, we conducted this systematic review and meta-analysis. METHODS: Relevant randomized controlled trials (RCTs) and observational studies (e.g., cohort studies, case-control studies, case-series, and case-reports) were included to summarize available evidence, both qualitatively and quantitatively. The Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, and ICUSHI were used for systematic research. Meta-analysis of the included studies was conducted using fixed-effect or random-effects models, depending on the degree of between-study heterogeneity. We assessed coronary artery and treatment outcomes of the interventions. The certainty of evidence and risk of bias were assessed using the GRADE and Cochrane risk of bias tool. The protocol of this review is registered with PROSPERO (CRD42016033079). RESULTS: Results: Of all searched studies, 183 studies were qualitatively analyzed. We finally included four randomized controlled trials with 456 patients in quantitative syntheses. Monoclonal antibodies and anti-cytokine biologics did not reduce the frequency of CAA (risk ratio [RR], 0.93; 95% confidence interval [95%CI], 0.65 to 1.32, low certainty of evidence), compared with the conventional treatment with IVIG. However, the frequency of treatment resistance (RR, 0.60; 95%CI, 0.38 to 0.95, moderate certainty of evidence) was reduced by the antibodies. We found no statistical differences in either "any adverse event" (RR, 0.92; 95%CI, 0.80 to 1.06, low certainty of evidence) or "adverse events attributable to the administration of the medication" (RR, 1.10; 95%CI, 0.72 to 1.69, low certainty of evidence) between the two groups. CONCLUSION: Conclusions: Although monoclonal antibodies and anti-cytokine biologics were not effective in reducing the frequency of CAA in KD patients, the frequency of treatment resistance might be reduced by those agents compared with conventional IVIG therapy alone.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Nomura O, Fukuda S, Ota E, et al. Monoclonal antibody and anti-cytokine biologics for Kawasaki disease: A systematic review and meta-analysis. Semin Arthritis Rheum. 2021. PMID: 34416626. doi:10.1016/j.semarthrit.2021.07.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。